Critical appraisal of ranibizumab in the treatment of diabetic macular edema
Michael W StewartDepartment of Ophthalmology, Mayo School of Medicine, Jacksonville, FL, USAAbstract: Diabetic retinopathy is the leading cause of blindness among individuals of working age in industrialized nations, with most of the vision loss resulting from diabetic macular edema (DME). The forma...
Main Author: | Stewart MW |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-06-01
|
Series: | Clinical Ophthalmology |
Online Access: | http://www.dovepress.com/critical-appraisal-of-ranibizumab-in-the-treatment-of-diabetic-macular-a13436 |
Similar Items
-
Treatment of diabetic macular edema by Ranibizumab with laser photocoagulation therapy
by: Yan Li, et al.
Published: (2018-08-01) -
Functional improvements of diabetic macular edema after treatment with Ranibizumab
by: Hussam O Elrashidy
Published: (2021-01-01) -
Pharmacoeconomic analysis of ranibizumab and aflibercept for treatment of diabetic macular edema
by: A. E. Cheberda, et al.
Published: (2018-05-01) -
Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
by: Ali Demircan, et al.
Published: (2018-01-01) -
Diabetic papillopathy with macular edema treated with intravitreal ranibizumab
by: Kim M, et al.
Published: (2013-11-01)